Zahedan Journal of Research in Medical Sciences
The Official Journal of Zahedan University of Medical Sciences
Image Credit:Zahedan J Res Med Sci
Outline
Effects of drug therapy of visceral leishmaniasis on serum level of IFN-γ, IL-10 and IL-12 in visceral leishmaniasis patients
Authors
Abstract
Background: Leishmaniosis has remained a serious public health problem in several parts of the developing world. Effective prophylacyic measurements are hampered by imprecise understanding of different aspects of the disease, including its immunoregulation. A better understanding of immunoregulation in human visceral leishmaniosis may be useful both for designing and evaluating immunoprophylaxis. Materials and Methods: This before-after interventional study investigated immunoregulatory mechanisms among 32 patients with visceral leishmaniasis in Shiraz (Iran) in 2007. The plasma cytokine (IFN-gamma, IL-10 and IL-12) levels of participants were measured before, during active disease and at different periods up to 2 months after treatment. Results: Elevated plasma levels of IFN-γ, IL-10 and IL-12 which were observed during active disease, decreased significantly after treatment. The main candidate for blunting IFN- γ activity seems to be IL-10, since the level of this cytokine which highly elevated in plasma decreased sharply after treatment (Before treatment 88.3±77.5, after treatment 25±18.3, 2months after treatment 517±1.9). difference between samples was significant (P<0/05) Discussion: Results suggest that IFN- γ and IL-10 are the molecules most likely involved in determining fate of the disease. After treatment, there is a long delay before the immune profile returns to its normal level which precludes using plasma cytokine levels as criteria for certain cure diagnosis of the disease.
Highlights
References
- 1.The references are available in pdf file.
Copyright
© 2008, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.
Similar Articles
Visceral Leishmaniasis: An Update and Literature Review
Karimi A, Alborzi A, Amanati A. Visceral Leishmaniasis: An Update and Literature Review. Arch Pediatr Infect Dis. 2016;4(3):e31612. doi: https://doi.org/10.5812/pedinfect.31612
Clinical Findings and Initial Treatment Response of Patients with Visceral Leishmaniasis Admitted in Ali asghar Children Hospital from 1976 to 2010 in Tehran, Iran
Nateghian A, Mousavi H. Clinical Findings and Initial Treatment Response of Patients with Visceral Leishmaniasis Admitted in Ali asghar Children Hospital from 1976 to 2010 in Tehran, Iran. Arch Clin Infect Dis. 2011;6(3):. doi:
Evaluation of a Novel Herbal Immunomodulator Drug (IMOD) in Treatment of Experimental Canine Visceral leishmaniasis
Malmasi A, Ziaie Ardestani B, Mohebali M, Akhoundi B, Ziaie S, et al. Evaluation of a Novel Herbal Immunomodulator Drug (IMOD) in Treatment of Experimental Canine Visceral leishmaniasis. Iran J Pharm Res. 2014;13(4):e125580. doi: https://doi.org/10.22037/ijpr.2014.1573
Characterization of Leishmania isolated from Kala- azar infected patients in Kermanshah using PCR
Fakhar M, Keyghobadi M, Akramipour R, Ghadiri K, Limouei M. Characterization of Leishmania isolated from Kala- azar infected patients in Kermanshah using PCR. J Kermanshah Univ Med Sci. 2011;15(2):e79382. doi:
Therapeutic and Adverse Effects of Glucantime Used for Treatment of Cutaneous Leishmaniasis.
Beheshti M. Therapeutic and Adverse Effects of Glucantime Used for Treatment of Cutaneous Leishmaniasis.. Shiraz E-Med J. 2007;8(4):. doi:
- Scopus by DOI: 0
Last Update: 3 weeks ago
- Scopus by Title: 0
Last Update: 3 weeks ago
- Scopus by Title (Ref): 1
Last Update: 3 weeks ago
- CrossRef: 0
Last Update: 10 hours ago
- OpenAlex: 0
Last Update: 13 hours ago
- OpenCitations: 0
Last Update: 4 days ago